---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037736"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2026-08-13T20:02:20+00:00"
generated_at: "2026-08-13T20:03:07.517018+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akari Q2 net loss $4.8M; raises $8.6M; AKTX-101 on track for mid-2027 Phase 1

## Summary
- Q2 2026 net loss $4.8M vs $1.9M YoY; R&D $2.1M up from $0.7M on IND-enabling work.
- Cash $7.7M at June 30, 2026 vs $5.2M at Dec 31, 2025; raised $8.6M gross in quarter.
- AKTX-101 progressing toward Phase 1 initiation planned for mid-2027; ASCO data on PH1 + KRAS inhibitor.
- Research collaboration with Whitehawk Therapeutics on dual-payload ADCs combining PH1 with topoisomerase I payload.

## SEC filing metadata
- accession: 0001493152-26-037736
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2026-08-13T20:02:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315226037736/0001493152-26-037736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315226037736/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037736
- JSON: https://secwatch.observer/filing/0001493152-26-037736.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.